<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276835</url>
  </required_header>
  <id_info>
    <org_study_id>NU 04V1</org_study_id>
    <secondary_id>NU-04V1</secondary_id>
    <secondary_id>CHIR-NU-04V1</secondary_id>
    <secondary_id>NU-IRB-0310-083</secondary_id>
    <nct_id>NCT00276835</nct_id>
  </id_info>
  <brief_title>Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer</brief_title>
  <official_title>A Pilot Study of the Effect of Genistein in Combination With High-Dose Interleukin-2 on Cell Expansion and Gene Expression in Patients With Metastatic Melanoma or Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Interleukin-2 may stimulate&#xD;
      the white blood cells, including natural killer cells, to kill melanoma or kidney cancer&#xD;
      cells. Giving genistein together with interleukin-2 may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving genistein together with&#xD;
      interleukin-2 works in treating patients with metastatic melanoma or kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Measure the differences in peak and duration of the expansion of circulating&#xD;
           CD4-positive, CD8-positive, and CD4-, CD25-, and CD56-positive cells (dim and bright) at&#xD;
           different time points during therapy with interleukin-2 (IL-2) alone and plus genistein&#xD;
           in patients with metastatic malignant melanoma or renal clear cell carcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the differences in peripheral blood mononuclear cell gene expression following&#xD;
           high-dose IL-2 with and without genistein and compare to baseline.&#xD;
&#xD;
        -  Determine the overall response rate (partial and complete) in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Determine the safety and toxic effects of these regimens in these patients.&#xD;
&#xD;
        -  Determine the time to progression in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive high-dose interleukin-2 IV over 15 minutes twice daily on days 1 and 15 and&#xD;
      3 times daily on days 2-5 and 16-19. Patients also receive oral genistein twice daily on days&#xD;
      10-19.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in peak and duration of the expansion of circulating CD4+, CD8+, and CD4+, CD25+, and CD56+ cells (dim and bright)</measure>
    <time_frame>Days 1, 8, 10, 15, 22, and 24 of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating plasma levels of TGF-beta</measure>
    <time_frame>Prior to and at end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Genistein and Interleukin-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-dose interleukin-2</intervention_name>
    <description>Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)</description>
    <arm_group_label>Genistein and Interleukin-2</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Aldesleukin</other_name>
    <other_name>Proleukin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>genistein</intervention_name>
    <description>Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)</description>
    <arm_group_label>Genistein and Interleukin-2</arm_group_label>
    <other_name>isoflavone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Documented histologically confirmed malignant melanoma or renal clear cell carcinoma&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  At least 1 measurable lesion that can be accurately measured in at least one dimension&#xD;
             with longest diameter &gt; 20 mm using conventional techniques OR &gt; 10 mm with spiral CT&#xD;
             scan&#xD;
&#xD;
               -  If the measurable disease is restricted to a solitary lesion, its neoplastic&#xD;
                  nature should be confirmed by cytology/histology&#xD;
&#xD;
               -  Clinical lesions will only be considered measurable when they are superficial&#xD;
                  (e.g., skin nodules or palpable lymph nodes)&#xD;
&#xD;
               -  The following are considered non-measurable lesions:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
                    -  Abdominal masses that are not confirmed and followed by imaging techniques&#xD;
&#xD;
          -  No CNS metastases by CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status &lt; 2&#xD;
&#xD;
          -  Life expectancy ≥ 4 months&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 mg/dL OR creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Platelets &gt; 100,000/mm³&#xD;
&#xD;
          -  WBC &gt; 3,500/mm³&#xD;
&#xD;
          -  No evidence of congestive heart failure&#xD;
&#xD;
          -  No symptom of coronary artery disease&#xD;
&#xD;
          -  No serious cardiac arrhythmias&#xD;
&#xD;
          -  A pretreatment cardiac stress test must be performed within 42 days of IL-2 treatment&#xD;
             if any cardiac symptoms present (patients with documented ischemia on the pretreatment&#xD;
             cardiac stress test will be excluded from the study)&#xD;
&#xD;
          -  Adequate pulmonary reserve&#xD;
&#xD;
               -  FEV_1 &gt; 75% of predicted&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No known HIV-positive patients&#xD;
&#xD;
          -  No evidence of active infection requiring antibiotic therapy&#xD;
&#xD;
          -  No contraindication to treatment with pressor agents&#xD;
&#xD;
          -  No significant medical disease which, in the opinion of the investigator, may&#xD;
             interfere with completion of the study&#xD;
&#xD;
          -  No history of another malignancy other than basal cell skin cancer within 5 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from all toxic effects of prior therapy&#xD;
&#xD;
          -  No radiotherapy, chemotherapy, or immunotherapy in the 4 weeks prior to the first dose&#xD;
             of the study treatment&#xD;
&#xD;
          -  No systemic corticosteroids in the 4 weeks prior to treatment&#xD;
&#xD;
          -  No previous investigational agent within 4 weeks prior to the start of the study&#xD;
&#xD;
          -  No prior interleukin-2 therapy&#xD;
&#xD;
          -  No organ allografts allowed&#xD;
&#xD;
          -  No concurrent radiotherapy, chemotherapy, or immunotherapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
          -  No concurrent chronic medication for asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M. Kuzel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Timothy Kuzel</investigator_full_name>
    <investigator_title>Timothy Kuzel, MD</investigator_title>
  </responsible_party>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

